The University of Chicago Header Logo

Sean Pitroda

TitleAssociate Professor
InstitutionUniversity of Chicago
DepartmentRadiation and Cellular Oncology
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    My long-term vision is to improve the treatment of metastatic disease through translational research. I believe this can only be achieved through challenging the prevailing view that metastases are always widespread and incurable. My laboratory utilizes integrative molecular analyses of clinical metastases, bioinformatics and computational tools, tumor models, molecular biology, immunologic analyses, and statistical modeling to investigate: (1) biological mechanisms that restrict the potential curability of patients with limited metastatic disease following localized therapies, such as surgery and ablative radiotherapy, and (2) the interplay between ablative radiotherapy and immune checkpoint blockade in patients with metastatic disease.

    We discovered the first biological basis for curable metastasis in patients with colorectal cancer who underwent surgical resection of limited de novo liver metastases, whereby robust adaptive immune activation in concert with favorable clinical factors was associated with a 10-year overall survival of ~95% following surgery (Nature Communications 2018). We recently validated these findings in the randomized phase III New EPOC trial (JAMA Oncology 2023). In addition, we discovered that concurrent administration of ablative radiotherapy with immunotherapy augmented local tumor immunity and improved survival in patients with highly aneuploid metastatic non-small cell lung cancer (NSCLC) (Nature Cancer 2022). We validated a tumor aneuploidy score as a novel biomarker of immunotherapy response across multiple human cancers (Nature Genetics 2022).

    Building upon these findings, we identified previously unknown mechanisms of immune suppression and novel strategies to augment the diminished immune responses in metastatic cancers. I anticipate these findings will ultimately have important implications in the delineation of those patients with potentially curable metastatic disease from those whose few metastases are part of a large cascade of widespread disease, thereby advancing the paradigm for the treatment of metastatic cancers. My technical expertise and clinical oncology training combined with my dedication to translational investigations make me well-suited to successfully execute the proposed research.

    Collapse Biography 
    Collapse education and training
    Illinois Institute of Technology, Chicago, ILB.S.06/2006Biomedical Engineering
    The University of Chicago, Chicago, ILM.D.06/2011Medicine
    The University of Chicago, Chicago, ILInternship06/2012Internal Medicine
    The University of Chicago, Chicago, ILResidency06/2016Radiation Oncology
    Memorial Sloan-Kettering Cancer Center, New York City, NY09/2015Spinal Radiosurgery
    Chicago Proton Center, Warrenville, IL10/2015Proton Radiotherapy
    Collapse awards and honors
    2020 - 2023LUNGevity Career Development Award, University of Chicago
    2019 - 2020Spotlight Grant on Tumor Biology, University of Chicago
    2019 - 2020Ullman Scholarship in Translational Cancer Immunology, University of Chicago
    2018 - 2018Best of ASTRO Basic/Translational Science Award for Junior Investigator in Radiation&Cancer Biology, American Society for Radiation Oncology
    2016 - 2016Distinguished Biomedical Engineering Alumni Award, Illinois Institute of Technology
    2011 - 2011Franklin McLean Medical Student Research Award, Pritzker School of Medicine, University of Chicago
    2011 - 2011Senior Research Award, Dept. of Radiation and Cellular Oncology, University of Chicago
    2010 - 2012Calvin Fentress Research Fellowship, University of Chicago
    2007 - 2007NIH Summer Research Fellowship, University of Chicago
    2006 - 2006Summa Cum Laude, Illinois Institute of Technology
    2005 - 2006Howard Hughes Medical Institute Research Fellowship, University of Chicago
    2005 - 2006Tau Beta Pi National Engineering Honor Society Winkler Scholarship, Illinois Institute of Technology
    2002 - 2006Heald Undergraduate Tuition Scholarship, Illinois Institute of Technology

    Collapse Featured Content 
    Collapse Twitter

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Katipally RR, Pitroda SP. Nontumor Cells in Tumor Samples Bias Expression-Based Models-Reply. JAMA Oncol. 2024 Feb 01; 10(2):260-261. PMID: 38153699.
      Citations:    Fields:    Translation:Humans
    2. Lynch C, Sweis RF, Modi P, Agarwal PK, Szmulewitz RZ, Stadler WM, O'Donnell PH, Liauw SL, Pitroda SP. Bladder-Preserving Trimodality Therapy With Capecitabine. Clin Genitourin Cancer. 2024 Jan 09. PMID: 38228414.
      Citations:    Fields:    
    3. Lynch C, Korpics MC, Katipally RR, Wu T, Bestvina CM, Pitroda S, Chmura SJ, Juloori A. Combined stereotactic body radiotherapy and immune checkpoint inhibition for liver metastases: safety and outcomes in a pooled analysis of three phase I trials. Int J Radiat Oncol Biol Phys. 2024 Jan 08. PMID: 38199382.
      Citations:    Fields:    
    4. Spurr LF, Pitroda SP. Exploiting tumor aneuploidy as a biomarker and therapeutic target in patients treated with immune checkpoint blockade. NPJ Precis Oncol. 2024 Jan 02; 8(1):1. PMID: 38167869; PMCID: PMC10761678.
    5. Wang L, Si W, Yu X, Piffko A, Dou X, Ding X, Bugno J, Yang K, Wen C, Zhang L, Chen D, Huang X, Wang J, Arina A, Pitroda S, Chmura SJ, He C, Liang HL, Weichselbaum R. Epitranscriptional regulation of TGF-ß pseudoreceptor BAMBI by m6A/YTHDF2 drives extrinsic radioresistance. J Clin Invest. 2023 Dec 15; 133(24). PMID: 38099498; PMCID: PMC10721150.
      Citations:    Fields:    Translation:HumansAnimals
    6. Wang L, Katipally RR, Liang HL, Yang K, Pitroda SP, He C, Weichselbaum RR. RNA m6A methylation and MDSCs: Roles and therapeutic implications for radiotherapy. Med. 2023 Dec 08; 4(12):863-874. PMID: 38070481; PMCID: PMC10751059.
      Citations:    Translation:HumansCells
    7. Liauw SL, Pitroda SP. Multidisciplinary Collaboration is Key. Int J Radiat Oncol Biol Phys. 2023 Dec 01; 117(5):1047-1048. PMID: 37980133.
      Citations:    Fields:    Translation:Humans
    8. Katipally RR, Martinez CA, Pugh SA, Bridgewater JA, Primrose JN, Domingo E, Maughan TS, Talamonti MS, Posner MC, Weichselbaum RR, Pitroda SP, with the S:CORT Consortium. Integrated Clinical-Molecular Classification of Colorectal Liver Metastases: A Biomarker Analysis of the Phase 3 New EPOC Randomized Clinical Trial. JAMA Oncol. 2023 09 01; 9(9):1245-1254. PMID: 37471075; PMCID: PMC10360005.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    9. Katipally RR, Pitroda SP, Weichselbaum RR, Hellman S. Oligometastases: Characterizing the Role of Epigenetic Regulation of Epithelial-Mesenchymal Transition. Clin Cancer Res. 2023 08 01; 29(15):2761-2766. PMID: 37115507; PMCID: PMC10687742.
      Citations:    Fields:    Translation:Humans
    10. Guzman ML, Gregucci F, Spada S, Barcellos-Hoff MH, Bhardwaj N, Chan Wah Hak C, Fiorentino A, Guha C, Harrington K, Herrera FG, Honeychurch J, Hong T, Iturri L, Jaffee E, Karam SD, Knott SRV, Koumenis C, Lyden D, Marciscano AE, Melcher A, Mondini M, Mondino A, Morris ZS, Pitroda S, Quezada SA, Santambrogio L, Shiao S, Stagg J, Telarovic I, Timmerman R, Vozenin MC, Weichselbaum R, Welsh J, Wilkins A, Xu C, Zappasodi R, Zou W, Bobard A, Demaria S, Galluzzi L, Deutsch E, Formenti SC. Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference. Oncoimmunology. 2023; 12(1):2222560. PMID: 37363104; PMCID: PMC10286673.
      Citations:    Fields:    Translation:Humans
    11. Wang L, Dou X, Chen S, Yu X, Huang X, Zhang L, Chen Y, Wang J, Yang K, Bugno J, Pitroda S, Ding X, Piffko A, Si W, Chen C, Jiang H, Zhou B, Chmura SJ, Luo C, Liang HL, He C, Weichselbaum RR. YTHDF2 inhibition potentiates radiotherapy antitumor efficacy. Cancer Cell. 2023 07 10; 41(7):1294-1308.e8. PMID: 37236197; PMCID: PMC10524856.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    12. Spurr LF, Weichselbaum RR, Pitroda SP. Author Correction: Tumor aneuploidy predicts survival following immunotherapy across multiple cancers. Nat Genet. 2023 Feb; 55(2):355. PMID: 36596861.
      Citations:    Fields:    
    13. Katipally RR, Spurr LF, Gutiontov SI, Turchan WT, Connell P, Juloori A, Malik R, Binkley MS, Jiang AL, Rouhani SJ, Chervin CS, Wanjari P, Segal JP, Ng V, Loo BW, Gomez DR, Bestvina CM, Vokes EE, Ferguson MK, Donington JS, Diehn M, Pitroda SP. STK11 Inactivation Predicts Rapid Recurrence in Inoperable Early-Stage Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2023 01; 7:e2200273. PMID: 36603171; PMCID: PMC10530422.
      Citations: 1     Fields:    Translation:Humans
    14. Rajeev-Kumar G, Pitroda SP. Synergizing radiotherapy and immunotherapy: Current challenges and strategies for optimization. Neoplasia. 2022 Dec 21; 36:100867. PMID: 36563632.
      Citations: 5     Fields:    
    15. Dhiman A, Vining CC, Witmer HDD, Sood D, Shergill A, Kindler H, Roggin KK, Posner MC, Ahmed OS, Liauw S, Pitroda S, Liao CY, Karrison T, Weichselbaum R, Eng OS, Catenacci DVT, Turaga KK, Polite B. ASO Visual Abstract: Phase II Prospective Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy with and without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels. Ann Surg Oncol. 2022 Dec; 29(Suppl 3):616-617. PMID: 35930113.
      Citations: 1     Fields:    Translation:CTClinical Trials
    16. Spurr LF, Martinez CA, Kang W, Chen M, Zha Y, Hseu R, Gutiontov SI, Turchan WT, Lynch CM, Pointer KB, Chang P, Murgu S, Husain AN, Cody B, Vokes EE, Bestvina CM, Patel JD, Diehn M, Gajewski TF, Weichselbaum RR, Chmura SJ, Pitroda SP. Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade. Nat Cancer. 2022 Nov 28. PMID: 36443406.
      Citations: 12     Fields:    
    17. Spurr LF, Weichselbaum RR, Pitroda SP. Tumor aneuploidy predicts survival following immunotherapy across multiple cancers. Nat Genet. 2022 12; 54(12):1782-1785. PMID: 36443443.
      Citations: 12     Fields:    Translation:Humans
    18. Spurr LF, Martinez CA, Katipally RR, Iyer SC, Pugh SA, Bridgewater JA, Primrose JN, Domingo E, Maughan TS, D'Angelica MI, Talamonti M, Posner MC, Connell PP, Weichselbaum RR, Pitroda SP. A proliferative subtype of colorectal liver metastases exhibits hypersensitivity to cytotoxic chemotherapy. NPJ Precis Oncol. 2022 Oct 14; 6(1):72. PMID: 36241710; PMCID: PMC9568565.
      Citations: 1     
    19. Turchan WT, Pitroda SP, Weichselbaum RR. Beyond the Visible Spectrum: Considering the Oligometastatic Hypothesis in the Light of a New Era. Int J Radiat Oncol Biol Phys. 2022 11 15; 114(4):581-586. PMID: 36244394.
      Citations: 2     Fields:    Translation:Humans
    20. Juloori A, Katipally RR, Lemons JM, Singh AK, Iyer R, Robbins JR, George B, Hall WA, Pitroda SP, Arif F, Fung J, Pillai A, Liao CY, Sharma M, Liauw SL. Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2023 01 01; 115(1):202-213. PMID: 36108891.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    21. Katipally RR, Pitroda SP, Juloori A, Chmura SJ, Weichselbaum RR. The oligometastatic spectrum in the era of improved detection and modern systemic therapy. Nat Rev Clin Oncol. 2022 09; 19(9):585-599. PMID: 35831494.
      Citations: 20     Fields:    Translation:Humans
    22. Korpics MC, Katipally RR, Partouche J, Cutright D, Pointer KB, Bestvina CM, Luke JJ, Pitroda SP, Dignam JJ, Chmura SJ, Juloori A. Predictors of Pneumonitis in Combined Thoracic Stereotactic Body Radiation Therapy and Immunotherapy. Int J Radiat Oncol Biol Phys. 2022 11 15; 114(4):645-654. PMID: 35753553.
      Citations: 5     Fields:    Translation:Humans
    23. Lakiza O, Lutze J, Vogle A, Williams J, Abukdheir A, Miller P, Liao C', Pitroda SP, Martinez C, Olivas A, Setia N, Kron SJ, Weichselbaum RR, Keutgen XM. Loss of MEN1 function impairs DNA repair capability of pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2022 03 21; 29(4):225-239. PMID: 35171113; PMCID: PMC9045673.
      Citations:    Fields:    Translation:HumansCells
    24. Turchan WT, Pitroda SP, Weichselbaum RR. Combined radio-immunotherapy: An opportunity to increase the therapeutic ratio of oligometastasis-directed radiotherapy. Neoplasia. 2022 05; 27:100782. PMID: 35303578; PMCID: PMC8931441.
      Citations: 1     Fields:    Translation:Humans
    25. Dhiman A, Vining CC, Witmer HDD, Sood D, Shergill A, Kindler H, Roggin KK, Posner MC, Ahmed OS, Liauw S, Pitroda S, Liao CY, Karrison T, Weichselbaum R, Polite B, Eng OS, Catenacci DVT, Turaga KK. Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Levels. Ann Surg Oncol. 2022 Jan 05. PMID: 34988836; PMCID: PMC8730296.
      Citations:    Fields:    
    26. Pathmarajah T, Katipally RR, Flores-Martinez E, Farrey KJ, Korpics MC, Sivananthan AP, Warnke PC, Chmura SJ, Yenice KM, Pitroda SP. Linear accelerator-based stereotactic radiosurgery for glossopharyngeal neuralgia is safe and effective - Report of two cases. J Radiosurg SBRT. 2022; 8(2):151-153. PMID: 36275126; PMCID: PMC9489069.
    27. Pointer KB, Pitroda SP, Weichselbaum RR. Radiotherapy and immunotherapy: open questions and future strategies. Trends Cancer. 2022 01; 8(1):9-20. PMID: 34740553.
      Citations: 23     Fields:    Translation:Humans
    28. Korpics MC, Katipally RR, Partouche J, Cutright D, Pointer KB, Bestvina CM, Luke J, Pitroda SP, Chmura SJ, Juloori A. Prospective Evaluation of Stereotactic Body Radiotherapy and Immunotherapy for Mediastinal and Hilar Lymph Node Metastases. Int J Radiat Oncol Biol Phys. 2021 Nov 01; 111(3S):S10. PMID: 34700387.
    29. Katipally RR, Korpics MC, Partouche J, Cutright D, Pointer KB, Bestvina CM, Luke JJ, Pitroda SP, Chmura SJ, Juloori A. Stereotactic Body Radiation Therapy and Immunotherapy in Abdominal and Pelvic Lymph Node Metastases. Int J Radiat Oncol Biol Phys. 2021 Nov 01; 111(3S):S58. PMID: 34700587.
    30. Pointer KB, Katipally RR, Bestvina CM, Juloori A, Partouche J, Patel JD, Pitroda SP, Vokes EE, Weichselbaum RR, Chmura SJ. Evaluation of Initial Metastatic Tumor Location and Radiation Response to Determine Outcomes in Patients Who Received Combination Stereotactic Body Radiotherapy and Immunotherapy for NSCLC. Int J Radiat Oncol Biol Phys. 2021 Nov 01; 111(3S):e449. PMID: 34701479.
    31. Gutiontov SI, Turchan WT, Spurr LF, Rouhani SJ, Chervin CS, Steinhardt G, Lager AM, Wanjari P, Malik R, Connell PP, Chmura SJ, Juloori A, Hoffman PC, Ferguson MK, Donington JS, Patel JD, Vokes EE, Weichselbaum RR, Bestvina CM, Segal JP, Pitroda SP. CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021 10 08; 11(1):20059. PMID: 34625620; PMCID: PMC8501138.
      Citations: 38     Fields:    Translation:Humans
    32. Turchan WT, Pitroda SP, Weichselbaum RR. Radiotherapy and Immunotherapy Combinations in the Treatment of Patients with Metastatic Disease: Current Status and Future Focus. Clin Cancer Res. 2021 10 01; 27(19):5188-5194. PMID: 34140404.
      Citations: 5     Fields:    Translation:Humans
    33. Bestvina CM, Pointer KB, Karrison T, Al-Hallaq H, Hoffman PC, Jelinek MJ, Juloori A, Melotek JM, Murgu S, Partouche J, Vokes EE, Weichselbaum RR, Pitroda SP, Patel JD, Chmura SJ. A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study. J Thorac Oncol. 2022 01; 17(1):130-140. PMID: 34500113.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    34. Turchan WT, Pitroda SP, Weichselbaum RR. Treatment of Cancer with Radio-Immunotherapy: What We Currently Know and What the Future May Hold. Int J Mol Sci. 2021 Sep 03; 22(17). PMID: 34502479; PMCID: PMC8431248.
      Citations: 4     Fields:    Translation:Humans
    35. Weichselbaum RR, Pitroda SP. Immunoradiotherapy goes club(bing). Nat Cancer. 2021 09; 2(9):871-872. PMID: 35121867.
      Citations: 1     Fields:    
    36. Gutiontov S, Pitroda S, Weichselbaum R. The Spectrum of Metastasis: An Opportunity for Cure? Semin Radiat Oncol. 2021 07; 31(3):174-179. PMID: 34090643.
      Citations: 4     Fields:    Translation:Humans
    37. Foster CC, Fleming GF, Karrison TG, Liao CY, Desai AV, Moroney JW, Ratain MJ, Nanda R, Polite BN, Hahn OM, O'Donnell PH, Vokes EE, Kindler HL, Hseu R, Janisch LA, Dai J, Hoffman MD, Weichselbaum RR, Pitroda SP, Chmura SJ, Luke JJ. Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20):5510-5518. PMID: 34168049.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    38. Onderdonk BE, Dorn PL, Martinez C, Arif F, Cloutier D, Antic T, Golden DW, Karrison T, Pitroda SP, Szmulewitz RZ, Liauw SL. A prospective clinical and transcriptomic feasibility study of oral-only hormonal therapy with radiation for unfavorable prostate cancer in men 70 years of age and older or with comorbidity. Cancer. 2021 08 01; 127(15):2631-2640. PMID: 33882144.
      Citations: 2     Fields:    Translation:HumansCells
    39. Yang K, Hou Y, Zhang Y, Liang H, Sharma A, Zheng W, Wang L, Torres R, Tatebe K, Chmura SJ, Pitroda SP, Gilbert JA, Fu YX, Weichselbaum RR. Suppression of local type I interferon by gut microbiota-derived butyrate impairs antitumor effects of ionizing radiation. J Exp Med. 2021 03 01; 218(3). PMID: 33496784; PMCID: PMC7844434.
      Citations: 28     Fields:    Translation:AnimalsCells
    40. Hou Y, Liang HL, Yu X, Liu Z, Cao X, Rao E, Huang X, Wang L, Li L, Bugno J, Fu Y, Chmura SJ, Wu W, Luo SZ, Zheng W, Arina A, Jutzy J, McCall AR, Vokes EE, Pitroda SP, Fu YX, Weichselbaum RR. Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity. Sci Transl Med. 2021 02 24; 13(582). PMID: 33627484; PMCID: PMC8710940.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    41. Gutiontov SI, Pitroda SP, Tran PT, Weichselbaum RR. (Oligo)metastasis as a Spectrum of Disease. Cancer Res. 2021 05 15; 81(10):2577-2583. PMID: 33452011.
      Citations: 8     Fields:    Translation:HumansAnimals
    42. Gutiontov SI, Pitroda SP, Weichselbaum RR. Oligometastasis: Past, Present, Future. Int J Radiat Oncol Biol Phys. 2020 11 01; 108(3):530-538. PMID: 32976785.
      Citations: 11     Fields:    Translation:Humans
    43. Luke JJ, Onderdonk BE, Bhave SR, Karrison T, Lemons JM, Chang P, Zha Y, Carll T, Krausz T, Huang L, Martinez C, Janisch LA, Hseu RD, Moroney JW, Patel JD, Khodarev NN, Salama JK, Ott PA, Fleming GF, Gajewski TF, Weichselbaum RR, Pitroda SP, Chmura SJ. Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. Clin Cancer Res. 2020 12 15; 26(24):6437-6444. PMID: 33028595; PMCID: PMC8561652.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    44. Gutiontov SI, Pitroda SP, Chmura SJ, Arina A, Weichselbaum RR. Cytoreduction and the Optimization Of Immune Checkpoint Inhibition with Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020 09 01; 108(1):17-26. PMID: 32819613.
      Citations: 12     Fields:    Translation:Humans
    45. Korpics MC, Polley MY, Bhave SR, Redler G, Pitroda SP, Luke JJ, Chmura SJ. A Validated T Cell Radiomics Score Is Associated With Clinical Outcomes Following Multisite SBRT and Pembrolizumab. Int J Radiat Oncol Biol Phys. 2020 09 01; 108(1):189-195. PMID: 32569799.
      Citations: 9     Fields:    Translation:HumansCells
    46. Foster CC, Pitroda SP, Weichselbaum RR. Definition, Biology, and History of Oligometastatic and Oligoprogressive Disease. Cancer J. 2020 Mar/Apr; 26(2):96-99. PMID: 32205532.
      Citations: 11     Fields:    Translation:Humans
    47. Yasumizu Y, Rajabi H, Jin C, Hata T, Pitroda S, Long MD, Hagiwara M, Li W, Hu Q, Liu S, Yamashita N, Fushimi A, Kui L, Samur M, Yamamoto M, Zhang Y, Zhang N, Hong D, Maeda T, Kosaka T, Wong KK, Oya M, Kufe D. Author Correction: MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer. Nat Commun. 2020 Feb 24; 11(1):1095. PMID: 32094369; PMCID: PMC7039914.
      Citations: 3     Fields:    
    48. Yasumizu Y, Rajabi H, Jin C, Hata T, Pitroda S, Long MD, Hagiwara M, Li W, Hu Q, Liu S, Yamashita N, Fushimi A, Kui L, Samur M, Yamamoto M, Zhang Y, Zhang N, Hong D, Maeda T, Kosaka T, Wong KK, Oya M, Kufe D. MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer. Nat Commun. 2020 01 17; 11(1):338. PMID: 31953400; PMCID: PMC6969104.
      Citations: 66     Fields:    Translation:HumansAnimalsCells
    49. Redler G, Stevens T, Cammin J, Malin M, Green O, Mutic S, Pitroda S, Aydogan B. Dosimetric Feasibility of Utilizing the ViewRay Magnetic Resonance Guided Linac System for Image-guided Spine Stereotactic Body Radiation Therapy. Cureus. 2019 Dec 12; 11(12):e6364. PMID: 31938646; PMCID: PMC6957030.
      Citations: 6     
    50. Arina A, Beckett M, Fernandez C, Zheng W, Pitroda S, Chmura SJ, Luke JJ, Forde M, Hou Y, Burnette B, Mauceri H, Lowy I, Sims T, Khodarev N, Fu YX, Weichselbaum RR. Tumor-reprogrammed resident T cells resist radiation to control tumors. Nat Commun. 2019 09 02; 10(1):3959. PMID: 31477729; PMCID: PMC6718618.
      Citations: 93     Fields:    Translation:AnimalsCells
    51. Pitroda SP, Weichselbaum RR. Integrated molecular and clinical staging defines the spectrum of metastatic cancer. Nat Rev Clin Oncol. 2019 09; 16(9):581-588. PMID: 31092903.
      Citations: 25     Fields:    Translation:Humans
    52. Pitroda SP, Chmura SJ, Weichselbaum RR. Integration of radiotherapy and immunotherapy for treatment of oligometastases. Lancet Oncol. 2019 08; 20(8):e434-e442. PMID: 31364595.
      Citations: 49     Fields:    Translation:HumansAnimals
    53. Foster CC, Pitroda SP, Weichselbaum RR. Beyond Palliation: The Rationale for Metastasis-Directed Therapy for Metastatic Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 09; 14(9):1510-1512. PMID: 31272814.
      Citations: 3     Fields:    Translation:Humans
    54. Ni L, Koshy M, Connell P, Pitroda S, Golden DW, Al-Hallaq H, Hubert G, Kauffman G, McCall A, Malik R. Heart V5 predicts cardiac events in unresectable lung cancer patients undergoing chemoradiation. J Thorac Dis. 2019 Jun; 11(6):2229-2239. PMID: 31372260; PMCID: PMC6626817.
      Citations: 1     
    55. Foster CC, Pitroda SP, Weichselbaum RR. Staging the Metastatic Spectrum Through Integration of Clinical and Molecular Features. J Clin Oncol. 2019 05 20; 37(15):1270-1276. PMID: 30939093.
      Citations: 7     Fields:    Translation:Humans
    56. Oshima G, Poli EC, Bolt MJ, Chlenski A, Forde M, Jutzy JMS, Biyani N, Posner MC, Pitroda SP, Weichselbaum RR, Khodarev NN. DNA Methylation Controls Metastasis-Suppressive 14q32-Encoded miRNAs. Cancer Res. 2019 02 01; 79(3):650-662. PMID: 30538122.
      Citations: 22     Fields:    Translation:HumansAnimalsCells
    57. Foster CC, Weichselbaum RR, Pitroda SP. Oligometastatic prostate cancer: Reality or figment of imagination? Cancer. 2019 02 01; 125(3):340-352. PMID: 30521067; PMCID: PMC6587458.
      Citations: 32     Fields:    Translation:Humans
    58. Pitroda SP, Khodarev NN, Huang L, Uppal A, Wightman SC, Ganai S, Joseph N, Pitt J, Brown M, Forde M, Mangold K, Xue L, Weber C, Segal JP, Kadri S, Stack ME, Khan S, Paty P, Kaul K, Andrade J, White KP, Talamonti M, Posner MC, Hellman S, Weichselbaum RR. Author Correction: Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. Nat Commun. 2018 11 13; 9(1):4827. PMID: 30425251; PMCID: PMC6233186.
      Citations:    Fields:    
    59. Sweis RF, Heiss B, Segal J, Ritterhouse L, Kadri S, Churpek JE, Allen K, Conway D, Marinier C, Smith ND, Pitroda SP, Stadler WM. Clinical Activity of Olaparib in Urothelial Bladder Cancer With DNA Damage Response Gene Mutations. JCO Precis Oncol. 2018 Nov; 2:1-7. PMID: 35135165.
      Citations: 7     Fields:    
    60. Leng J, Akthar AS, Szmulewitz RZ, O'Donnell PH, Sweis RF, Pitroda SP, Smith N, Steinberg GD, Liauw SL. Safety and Efficacy of Hypofractionated Radiotherapy With Capecitabine in Elderly Patients With Urothelial Carcinoma. Clin Genitourin Cancer. 2019 Feb; 17(1):e12-e18. PMID: 30392939.
      Citations: 2     Fields:    Translation:Humans
    61. Pitroda SP, Khodarev NN, Huang L, Uppal A, Wightman SC, Ganai S, Joseph N, Pitt J, Brown M, Forde M, Mangold K, Xue L, Weber C, Segal JP, Kadri S, Stack ME, Khan S, Paty P, Kaul K, Andrade J, White KP, Talamonti M, Posner MC, Hellman S, Weichselbaum RR. Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. Nat Commun. 2018 05 04; 9(1):1793. PMID: 29728604; PMCID: PMC5935683.
      Citations: 105     Fields:    Translation:Humans
    62. Pitroda SP, Stack ME, Liu GF, Song SS, Chen L, Liang H, Parekh AD, Huang X, Roach P, Posner MC, Weichselbaum RR, Khodarev NN. JAK2 Inhibitor SAR302503 Abrogates PD-L1 Expression and Targets Therapy-Resistant Non-small Cell Lung Cancers. Mol Cancer Ther. 2018 04; 17(4):732-739. PMID: 29467274.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    63. Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, Al-Hallaq HA, Arina A, Khodarev NN, Janisch L, Chang P, Patel JD, Fleming GF, Moroney J, Sharma MR, White JR, Ratain MJ, Gajewski TF, Weichselbaum RR, Chmura SJ. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 06 01; 36(16):1611-1618. PMID: 29437535; PMCID: PMC5978468.
      Citations: 253     Fields:    Translation:HumansCTClinical Trials
    64. Pitroda SP, Bao R, Andrade J, Weichselbaum RR, Connell PP. Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer. Clin Cancer Res. 2017 Aug 01; 23(15):4493-4500. PMID: 28341751; PMCID: PMC5540755.
      Citations: 8     Fields:    Translation:HumansCells
    65. Meng Y, Mauceri HJ, Khodarev NN, Darga TE, Pitroda SP, Beckett MA, Kufe DW, Weichselbaum RR. Ad.Egr-TNF and Local Ionizing Radiation Suppress Metastases by Interferon-ß-Dependent Activation of Antigen-specific CD8+ T Cells. Mol Ther. 2010 May; 18(5):912-920. PMID: 28178556.
    66. Oshima G, Stack ME, Wightman SC, Bryan D, Poli E, Xue L, Skowron KB, Uppal A, Pitroda SP, Huang X, Posner MC, Hellman S, Weichselbaum RR, Khodarev NN. Advanced Animal Model of Colorectal Metastasis in Liver: Imaging Techniques and Properties of Metastatic Clones. J Vis Exp. 2016 11 30; (117). PMID: 27929457; PMCID: PMC6145586.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    67. Skowron KB, Pitroda SP, Namm JP, Balogun O, Beckett MA, Zenner ML, Fayanju O, Huang X, Fernandez C, Zheng W, Qiao G, Chin R, Kron SJ, Khodarev NN, Posner MC, Steinberg GD, Weichselbaum RR. Basal Tumor Cell Isolation and Patient-Derived Xenograft Engraftment Identify High-Risk Clinical Bladder Cancers. Sci Rep. 2016 10 24; 6:35854. PMID: 27775025; PMCID: PMC5075783.
      Citations: 8     Fields:    Translation:HumansAnimals
    68. Rajabi H, Tagde A, Alam M, Bouillez A, Pitroda S, Suzuki Y, Kufe D. DNA methylation by DNMT1 and DNMT3b methyltransferases is driven by the MUC1-C oncoprotein in human carcinoma cells. Oncogene. 2016 12 15; 35(50):6439-6445. PMID: 27212035; PMCID: PMC5121097.
      Citations: 46     Fields:    Translation:HumansCells
    69. Wong AC, Watson SP, Pitroda SP, Son CH, Das LC, Stack ME, Uppal A, Oshima G, Khodarev NN, Salama JK, Weichselbaum RR, Chmura SJ. Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). Cancer. 2016 07 15; 122(14):2242-50. PMID: 27206146.
      Citations: 44     Fields:    Translation:Humans
    70. Ranoa DR, Parekh AD, Pitroda SP, Huang X, Darga T, Wong AC, Huang L, Andrade J, Staley JP, Satoh T, Akira S, Weichselbaum RR, Khodarev NN. Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs. Oncotarget. 2016 May 03; 7(18):26496-515. PMID: 27034163; PMCID: PMC5041995.
      Citations: 87     Fields:    Translation:HumansAnimalsCells
    71. Bouillez A, Rajabi H, Pitroda S, Jin C, Alam M, Kharbanda A, Tagde A, Wong KK, Kufe D. Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas. Cancer Res. 2016 Mar 15; 76(6):1538-48. PMID: 26833129; PMCID: PMC4794417.
      Citations: 58     Fields:    Translation:HumansAnimalsCells
    72. Oshima G, Wightman SC, Uppal A, Stack ME, Pitroda SP, Oskvarek JJ, Huang X, Posner MC, Hellman S, Weichselbaum RR, Khodarev NN. Imaging of tumor clones with differential liver colonization. Sci Rep. 2015 Jun 22; 5:10946. PMID: 26094901; PMCID: PMC4476146.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    73. Wightman SC, Uppal A, Pitroda SP, Ganai S, Burnette B, Stack M, Oshima G, Khan S, Huang X, Posner MC, Weichselbaum RR, Khodarev NN. Oncogenic CXCL10 signalling drives metastasis development and poor clinical outcome. Br J Cancer. 2015 Jul 14; 113(2):327-35. PMID: 26042934; PMCID: PMC4506383.
      Citations: 67     Fields:    Translation:AnimalsCells
    74. Khodarev NN, Pitroda SP, Weichselbaum RR. microRNAs and oligometastasis. Aging (Albany NY). 2015 Mar; 7(3):146-7. PMID: 25868522; PMCID: PMC4394724.
      Citations: 5     Fields:    Translation:Humans
    75. Uppal A, Wightman SC, Mallon S, Oshima G, Pitroda SP, Zhang Q, Huang X, Darga TE, Huang L, Andrade J, Liu H, Ferguson MK, Greene GL, Posner MC, Hellman S, Khodarev NN, Weichselbaum RR. 14q32-encoded microRNAs mediate an oligometastatic phenotype. Oncotarget. 2015 Feb 28; 6(6):3540-52. PMID: 25686838; PMCID: PMC4414135.
      Citations: 57     Fields:    Translation:HumansAnimalsCells
    76. Takahashi H, Jin C, Rajabi H, Pitroda S, Alam M, Ahmad R, Raina D, Hasegawa M, Suzuki Y, Tagde A, Bronson RT, Weichselbaum R, Kufe D. MUC1-C activates the TAK1 inflammatory pathway in colon cancer. Oncogene. 2015 Oct 01; 34(40):5187-97. PMID: 25659581; PMCID: PMC4530107.
      Citations: 61     Fields:    Translation:HumansAnimalsCells
    77. Pitroda SP, Pashtan IM, Logan HL, Budke B, Darga TE, Weichselbaum RR, Connell PP. DNA repair pathway gene expression score correlates with repair proficiency and tumor sensitivity to chemotherapy. Sci Transl Med. 2014 Mar 26; 6(229):229ra42. PMID: 24670686; PMCID: PMC4889008.
      Citations: 45     Fields:    Translation:HumansCells
    78. Widau RC, Parekh AD, Ranck MC, Golden DW, Kumar KA, Sood RF, Pitroda SP, Liao Z, Huang X, Darga TE, Xu D, Huang L, Andrade J, Roizman B, Weichselbaum RR, Khodarev NN. RIG-I-like receptor LGP2 protects tumor cells from ionizing radiation. Proc Natl Acad Sci U S A. 2014 Jan 28; 111(4):E484-91. PMID: 24434553; PMCID: PMC3910628.
      Citations: 45     Fields:    Translation:HumansAnimalsCells
    79. Pitroda SP, Zhou T, Sweis RF, Filippo M, Labay E, Beckett MA, Mauceri HJ, Liang H, Darga TE, Perakis S, Khan SA, Sutton HG, Zhang W, Khodarev NN, Garcia JG, Weichselbaum RR. Tumor endothelial inflammation predicts clinical outcome in diverse human cancers. PLoS One. 2012; 7(10):e46104. PMID: 23056240; PMCID: PMC3464251.
      Citations: 27     Fields:    Translation:HumansAnimalsCells
    80. Jin C, Rajabi H, Pitroda S, Li A, Kharbanda A, Weichselbaum R, Kufe D. Cooperative interaction between the MUC1-C oncoprotein and the Rab31 GTPase in estrogen receptor-positive breast cancer cells. PLoS One. 2012; 7(7):e39432. PMID: 22792175; PMCID: PMC3392244.
      Citations: 26     Fields:    Translation:HumansCells
    81. Liauw SL, Pitroda SP, Eggener SE, Stadler WM, Pelizzari CA, Vannier MW, Oto A. Evaluation of the prostate bed for local recurrence after radical prostatectomy using endorectal magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2013 Feb 01; 85(2):378-84. PMID: 22717242.
      Citations: 32     Fields:    Translation:Humans
    82. MacDermed DM, Khodarev NN, Pitroda SP, Edwards DC, Pelizzari CA, Huang L, Kufe DW, Weichselbaum RR. MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients. BMC Med Genomics. 2010 May 06; 3:16. PMID: 20459602; PMCID: PMC2876055.
      Citations: 41     Fields:    Translation:HumansAnimalsCells
    83. Meng Y, Mauceri HJ, Khodarev NN, Darga TE, Pitroda SP, Beckett MA, Kufe DW, Weichselbaum RR. Ad.Egr-TNF and local ionizing radiation suppress metastases by interferon-beta-dependent activation of antigen-specific CD8+ T cells. Mol Ther. 2010 May; 18(5):912-20. PMID: 20197756; PMCID: PMC2890103.
      Citations: 22     Fields:    Translation:HumansAnimalsCells
    84. Khodarev N, Ahmad R, Rajabi H, Pitroda S, Kufe T, McClary C, Joshi MD, MacDermed D, Weichselbaum R, Kufe D. Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer. Oncogene. 2010 Feb 11; 29(6):920-9. PMID: 19915608; PMCID: PMC2820589.
      Citations: 59     Fields:    Translation:HumansAnimalsCells
    85. Pitroda SP, Wakim BT, Sood RF, Beveridge MG, Beckett MA, MacDermed DM, Weichselbaum RR, Khodarev NN. STAT1-dependent expression of energy metabolic pathways links tumour growth and radioresistance to the Warburg effect. BMC Med. 2009 Nov 05; 7:68. PMID: 19891767; PMCID: PMC2780454.
      Citations: 85     Fields:    Translation:HumansAnimalsCells
    86. Khodarev NN, Roach P, Pitroda SP, Golden DW, Bhayani M, Shao MY, Darga TE, Beveridge MG, Sood RF, Sutton HG, Beckett MA, Mauceri HJ, Posner MC, Weichselbaum RR. STAT1 pathway mediates amplification of metastatic potential and resistance to therapy. PLoS One. 2009 Jun 08; 4(6):e5821. PMID: 19503789; PMCID: PMC2688034.
      Citations: 66     Fields:    Translation:AnimalsCells
    87. Efimova EV, Liang H, Pitroda SP, Labay E, Darga TE, Levina V, Lokshin A, Roizman B, Weichselbaum RR, Khodarev NN. Radioresistance of Stat1 over-expressing tumour cells is associated with suppressed apoptotic response to cytotoxic agents and increased IL6-IL8 signalling. Int J Radiat Biol. 2009 May; 85(5):421-31. PMID: 19437244; PMCID: PMC2690884.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    88. Khodarev NN, Pitroda SP, Beckett MA, MacDermed DM, Huang L, Kufe DW, Weichselbaum RR. MUC1-induced transcriptional programs associated with tumorigenesis predict outcome in breast and lung cancer. Cancer Res. 2009 Apr 01; 69(7):2833-7. PMID: 19318547; PMCID: PMC3034477.
      Citations: 69     Fields:    Translation:HumansAnimalsCells
    89. Pitroda SP, Khodarev NN, Beckett MA, Kufe DW, Weichselbaum RR. MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment. Proc Natl Acad Sci U S A. 2009 Apr 07; 106(14):5837-41. PMID: 19289846; PMCID: PMC2656554.
      Citations: 65     Fields:    Translation:Humans
    90. Mauceri HJ, Beckett MA, Liang H, Sutton HG, Pitroda S, Galka E, Efimova E, Darga T, Khodarev NN, King CR, Posner MC, Hellman S, Kufe DW, Weichselbaum RR. Translational strategies exploiting TNF-alpha that sensitize tumors to radiation therapy. Cancer Gene Ther. 2009 Apr; 16(4):373-81. PMID: 18974777; PMCID: PMC5705082.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    91. Pitroda S, Angstadt M, McCloskey MS, Coccaro EF, Phan KL. Emotional experience modulates brain activity during fixation periods between tasks. Neurosci Lett. 2008 Oct 03; 443(2):72-6. PMID: 18674589; PMCID: PMC2558674.
      Citations: 3     Fields:    Translation:Humans
    Pitroda's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (302)
    Co-Authors (78)
    Similar People (60)
    Same Department Expand Description
    Physical Neighbors